ライフサイエンスコーパス: PHQ

1 PHQ-2 scores were extracted from the answers to the firs

2 PHQ-9 and GAD-7 scores were significantly reduced at all

3 PHQ-9 data were available for 614 patients at 3 months a

4 nts [7.3]; BA 7.8 [6.5], mean difference 0.0 PHQ-9 points [-1.5 to 1.6], p=0.99).

5 8.4 PHQ-9 points [7.0], mean difference 0.1 PHQ-9 points [95% CI -1.3 to 1.5], p=0.89; PP: CBT 7.9 P

6 re extracted from the answers to the first 2 PHQ-9 questions.

7 d the 2-item Patient Health Questionnaire 2 (PHQ-2; range, 0-6; >=3 indicates possible depressive dis

8 The Patient Health Questionnaire-2 (PHQ-2) consists of the first 2 items of the PHQ-9 (which

9 en patients (Patient Health Questionnaire-2 [PHQ-2], GAD-2, and an item about panic attacks), and a d

10 (mITT: CBT 8.4 PHQ-9 points [SD 7.5], BA 8.4 PHQ-9 points [7.0], mean difference 0.1 PHQ-9 points [95

11 BA was non-inferior to CBT (mITT: CBT 8.4 PHQ-9 points [SD 7.5], BA 8.4 PHQ-9 points [7.0], mean d

12 red via the Patient Health Questionnaire-4 ([PHQ-4]; range, 0-12; scores of more than 5 indicate elev

13 5]), with a between-group difference of -1.5 PHQ-9 points (95% CI, -2.6 to -0.4; P = .009; d = -0.36)

14 mpleted the Personal Health Questionnaire-8 (PHQ-8).

15 The non-inferiority margin was 1.9 PHQ-9 points.

16 ts [95% CI -1.3 to 1.5], p=0.89; PP: CBT 7.9 PHQ-9 points [7.3]; BA 7.8 [6.5], mean difference 0.0 PH

17 an 14 on the Patient Health Questionnaire 9 (PHQ-9) indicating moderately severe to severe depression

18 on severity [Patient Health Questionnaire 9 (PHQ-9) score of <19 vs >/=19], antidepressant use, and r

19 and email, a Patient Health Questionnaire 9 (PHQ-9) score of at least 10, and a confirmed diagnosis o

20 ssion on the Patient Health Questionnaire 9 (PHQ-9) were randomised to either HAP plus enhanced usual

21 sured by the Patient Health Questionnaire 9 (PHQ-9), a self-report questionnaire validated to correla

22 ed using the Patient Health Questionnaire-9 (PHQ-9) and categorized using a validated cut point (PHQ-

23 eks with the Patient Health Questionnaire-9 (PHQ-9) and was scored diagnostically by using Diagnostic

24 eater on the Patient Health Questionnaire-9 (PHQ-9) and were randomly assigned to CCBT or TAU for 12

25 d the use of Patient Health Questionnaire-9 (PHQ-9) as depression severity dimension) may improve cli

26 essed by the Patient Health Questionnaire-9 (PHQ-9) depression scale compared with 50% of EUC patient

27 uracy of the Patient Health Questionnaire-9 (PHQ-9) depression screening tool.

28 nistered the Patient Health Questionnaire-9 (PHQ-9) during the index AMI admission.

29 st 10 on the Patient Health Questionnaire-9 (PHQ-9) from antenatal clinics in Goa.

30 score on the Patient Health Questionnaire-9 (PHQ-9) indicated moderate depression (score 10-14) or mo

31 ed using the Patient Health Questionnaire-9 (PHQ-9), and all-cause mortality was the primary outcome.

32 ut measures, Patient Health Questionnaire-9 (PHQ-9), and Generalized Anxiety Disorder Scale-7 (GAD-7)

33 LBI) and the Patient Health Questionnaire-9 (PHQ-9), and provided demographic data and practice infor

34 ined via the Patient Health Questionnaire-9 (PHQ-9), the Generalised Anxiety Disorder-7 (GAD-7) quest

35 ompleted the Patient Health Questionnaire-9 (PHQ-9), which included Item 9 that asks patients if they

36 st 10 on the Patient Health Questionnaire-9 (PHQ-9), who we recruited from households within communit

37 >/=10 on the Patient Health Questionnaire-9 (PHQ-9).

38 ion with the Patient Health Questionnaire-9 (PHQ-9).

39 rsion of the Patient Health Questionnaire-9 (PHQ-9).

40 sed with the Patient Health Questionnaire-9 (PHQ-9).

41 sured by the Patient Health Questionnaire-9 (PHQ-9); county-level community mobility estimates from m

42 x (ISI), and Patient Health Questionnaire-9 (PHQ-9; depression) scores.

43 n screening (Patient Health Questionnaire 9 [PHQ-9]), social support index, food insecurity, and hous

44 depression (Patient Health Questionnaire-9 [PHQ-9] score >=10) from internet advertising and the UK

45 ve symptoms (Patient Health Questionnaire-9 [PHQ-9] score 10) who were being treated for hypertension

46 , defined by Patient Health Questionnaire-9 [PHQ-9] score) conducted from June 2010 through March 201

47 ve symptoms (Patient Health Questionnaire-9 [PHQ-9] scores >=5) and no MDD episode in the past 6 mont

48 depressive (Patient Health Questionnaire-9 [PHQ-9]), posttraumatic stress disorder (PTSD; PTSD Check

49 A PHQ motif near the amino termini of gammaretroviral enve

50 reened positive for depression (defined as a PHQ-9 score of at least 10).

51 nd the prevalence of remission (defined as a PHQ-9 score of less than 5) in participants with availab

52 tly transactivated by adding to the assays a PHQ-containing SU or receptor-binding subdomain (RBD) de

53 Depression was defined by a PHQ-9 score of >/=10.

54 documented in the medical records despite a PHQ score >/=10.

55 0 individuals and 170 (29%) of the 585 had a PHQ diagnosis.

56 and higher remission (147 [64%] of 230 had a PHQ-9 score of <10 in the HAP plus EUC group vs 91 [39%]

57 A random sample of those with a PHQ-9 score that was less than 9 were selected for a CID

58 c-statistics the potential of both PHQ-2 and PHQ-9 to predict death and hospitalization was similar.

59 To analyze associations of PHQ-2 and PHQ-9 with both, death and rehospitalization, univariabl

60 Both, PHQ-2 and PHQ-9, predicted death in univariable analysis (hazard r

61 sociated with underreporting on the AAFQ and PHQ but overreporting on PAR.

62 a negative correlation between CarCGQoL and PHQ-9 scores (r = -0.66, P < .01), indicating that worse

63 ith sustained reduction in headache days and PHQ-9 and GAD-7 scores in the analysis population (n=715

64 r analysis of pooled questions of CNS-LS and PHQ-9 identified three underlying factors (laughter, cry

65 the two self-report instruments (CNS-LS and PHQ-9) discriminate well between PBA and depression, the

66 Mean PCS, MCS, and PHQ-9 scores were relatively stable over a median of 3 y

67 reporting decreased with age for the PAR and PHQ.

68 (R(2) = 7.6, 4.8, and 3.4 for AAFQ, PAR, and PHQ, respectively).

69 ) to 79.4, 67.8, and 68.7 for AAFQ, PAR, and PHQ, respectively.

70 tified by site and minimised by practice and PHQ-9 score.

71 s responding to the intervention (defined as PHQ-9 <10 and reduction in PHQ-9 of >/=5 points) at 4 mo

72 Participants with at PHQ-9 scores >=5 at baseline showed greater improvement

73 There was good agreement between PHQ diagnoses and those of independent mental health pro

74 firmed by c-statistics the potential of both PHQ-2 and PHQ-9 to predict death and hospitalization was

75 Both, PHQ-2 and PHQ-9, predicted death in univariable analysis

76 severity of depressive symptoms (assessed by PHQ-9 score) and the prevalence of remission (defined as

77 The severity of depression (assessed by PHQ-9 scores; standardised mean difference -0.13, 95% CI

78 ation of PHQ-2 (with cutoff >=2) followed by PHQ-9 (with cutoff >=10) had similar sensitivity but hig

79 for PHQ-2 scores of 2 or greater followed by PHQ-9 scores of 10 or greater (0.82 [0.76-0.86]) was not

80 ysis predicts Cu-PHE, Cu-PHQ, Cd-PHE, and Cd-PHQ mixtures at the Canadian Water Quality Guideline con

81 r all Cu-PHE, Cu-PHQ, and several Cd-PHE, Cd-PHQ, and Ni-PHE mixtures.

82 data meta-analysis of studies that compared PHQ scores with major depression diagnoses, the combinat

83 tions in or adjacent to the highly conserved PHQ motif present at the N terminus of the envelope surf

84 le and more feasible than the time-consuming PHQ-9 to identify patients at an increased risk of adver

85 ore-than-additive mortality of Cu-PHE and Cu-PHQ mixtures.

86 ve lethality was observed for all Cu-PHE, Cu-PHQ, and several Cd-PHE, Cd-PHQ, and Ni-PHE mixtures.

87 Our analysis predicts Cu-PHE, Cu-PHQ, Cd-PHE, and Cd-PHQ mixtures at the Canadian Water Q

88 models based on extensive demographic data, PHQ-9 scores, and the outcomes from the Mood Disorder Qu

89 asures assessed anxiety (GAD-7), depression (PHQ-9), dissociation (Cambridge Depersonalization Scale,

90 versus 0.87 (0.20)), anxiety and depression (PHQ-4 total score 3.59 (3.71) versus 1.28 (2.67)) and ae

91 Among patients with baseline depression (PHQ-9 score > or = 10), there was greater improvement in

92 nterns who screened positive for depression (PHQ-9 score >=10) during their internship, mean PHQ-9 sc

93 ry version II and remission from depression (PHQ-9 score of <10) at 3 months in the intention-to-trea

94 participants with at least mild depression (PHQ-9 >= 5).

95 patients with AMI having: (1) no depression (PHQ-9<10; reference); (2) treated depression; and (3) un

96 estionnaire includes measures of depression (PHQ-9) and substance abuse (ASSIST).

97 of suicidal ideation, or severe depression (PHQ-9 score >20).

98 e proportion of individuals with depression (PHQ-9 score >9) who sought treatment for symptoms of dep

99 uoxetine hydrochloride and placebo developed PHQ-9 scores of 9 or higher during the trial (placebo, 7

100 on meeting criteria for depressive disorder (PHQ-9 score >/=10) at 4- and 12-month follow-up.

101 ng; (2) whether they had based their earlier PHQ responses on symptom frequency, being bothered by sy

102 esult for depression, defined as an elevated PHQ-9 score of 10 or greater (indicating moderate to sev

103 rizons (30, 90, 180, and 365 days) following PHQ-9M screenings.

104 ain Intensity subscale, and -3.7 vs -1.2 for PHQ-9.

105 or FOSQ scores, 7 of 23 patients (30.4%) for PHQ-9 scores, and 11 of 25 patients (44.0%) for ISI scor

106 vs 53 of 217 PAP group patients (24.4%) for PHQ-9 scores, and 23 of 49 HNS group patients (46.9%) vs

107 r semistructured interviews, sensitivity for PHQ-2 scores of 2 or greater followed by PHQ-9 scores of

108 ee host-range groups, A, B, and C, lack full PHQ motifs, but most members have an H residue at positi

109 of participants needing to complete the full PHQ-9 by 57% (56%-58%).

110 entify patients for evaluation with the full PHQ-9.

111 icipants (20.2%) treated with fluoxetine had PHQ-9 scores of 9 or higher (P = .70).

112 patients (18.9%) in the fluoxetine group had PHQ-9 scores of 9 or higher.

113 rnout, and 16.1% (N=336) of participants had PHQ-9 scores >=10, suggesting a diagnosis of major depre

114 A total of 98% of psychiatrists who had PHQ-9 scores >=10 also had OLBI scores >35.

115 iety Disorder-7 (GAD-7), and Patient Health (PHQ-9) questionnaires.

116 ce were significantly associated with higher PHQ-9 scores.

117 However, PHQ increased the tissue concentration of Cu in juvenile

118 isfaction (multiple R = 0.46), and change in PHQ-8 score (multiple R = 0.13).

119 nge in mood scores over time; mean change in PHQ-8 score was not significantly different from zero (m

120 ement was also found for 5-point decrease in PHQ-9 score among 72.2% of intervention patients compare

121 aining (posttreatment: largest difference in PHQ-9 score [functional analysis], -0.09 [90% CI, -0.56

122 9]; 6-month follow-up: largest difference in PHQ-9 score [relaxation], -0.18 [90% CI, -0.61 to 0.25])

123 led to significantly greater improvement in PHQ-9 scores than TAU at posttreatment (mean difference,

124 ed with survival after adding improvement in PHQ-9 scores to the survival model.

125 However, improvement in PHQ-9 scores was not associated with improved survival,

126 assigned to EPC had greater improvements in PHQ-9 scores at 12 weeks (P < .001); among patients with

127 iencing a >=1 severity category reduction in PHQ-9 and GAD-7.

128 ntion (defined as PHQ-9 <10 and reduction in PHQ-9 of >/=5 points) at 4 months after randomisation.

129 response was considered >/= 50% reduction in PHQ-9 scores at 12 weeks.

130 lysis, significant improvements were seen in PHQ-9 scores for HNS vs PAP (least square means, -4.06 [

131 studies that used semistructured interviews, PHQ-2 sensitivity and specificity (95% CI) were 0.91 (0.

132 e proportion with scores >/=15 on the 9-item PHQ dropped from 15.1% [38 of 252] to 8.0% [18 of 225] a

133 ither a Patient Health Questionnaire-9 item (PHQ-9) score of 10 or greater, a Generalized Anxiety Dis

134 ing the Patient Health Questionnaire 9-item (PHQ-9).

135 ession (Patient Health Questionnaire 9-item [PHQ-9] score >/=10) on 2 occasions or who screened posit

136 for age, sex, and the other screening items, PHQ-2 items independently predicted depression (little i

137 ord count was positively associated with log PHQ-4 total (0.06 SD, 95%CI [0.02, 0.09]), anxiety (0.05

138 Collaborative care resulted in lower PHQ-9 scores vs usual care at 4-month follow-up (mean sc

139 were women; mean BMI of 36.7 [SD, 6.4]; mean PHQ-9 score of 13.8 [SD, 3.1]; and mean SCL-20 score of

140 ' mean OLBI score was 40.4 (SD=7.9) and mean PHQ-9 score was 5.1 (SD=4.9).

141 whom 976 (83%) were female and baseline mean PHQ-9 score was 13.7 (SD 2.6).

142 in symptom severity between the groups (mean PHQ-9 score 3.47 [SD 4.49] in the intervention group vs

143 statistically significant reduction in mean PHQ-9 depression scores at 3 months for acupuncture (-2.

144 -9 score >=10) during their internship, mean PHQ-9 scores were significantly higher at both 5 years (

145 ment differences remained at 12 months (mean PHQ-9 score with collaborative care, 5.93 vs with usual

146 The mean PHQ-9 score was 7, corresponding to a symptom severity o

147 ems overlapping with the depression measure (PHQ-9) and the menstruation complaints item which biases

148 Overall, 759 (18.7%) patients met PHQ-9 criteria for depression and 231 (30.4%) were treat

149 The proportion of participants who met PHQ-9 criteria for depression increased from 3.9% prior

150 ient Health Questionnaire depression module (PHQ-9) is a 9-item self-administered instrument used for

151 At 3 months, PHQ-9 scores were 1.98 (95% CI, 0.60-3.36) points lower

152 117 (32%) of the 363 patients with 1 or more PHQ diagnoses not previously recognized.

153 ssionals (for the diagnosis of any 1 or more PHQ disorder, kappa = 0.65; overall accuracy, 85%; sensi

154 To analyze associations of PHQ-2 and PHQ-9 with both, death and rehospitalization,

155 jor depression diagnoses, the combination of PHQ-2 (with cutoff >=2) followed by PHQ-9 (with cutoff >

156 ors were assessed as potential predictors of PHQ-9 depression scores.

157 %) reported 5 points or greater worsening of PHQ-9 score at second survey.

158 tion prescriptions, and were asymptomatic on PHQ-2 or PHQ-9.

159 ipant data meta-analysis (IPDMA) database on PHQ-9 screening accuracy to represent a hypothetical pop

160 There were no effects on PHQ-8 measured depression score at the 12-week follow-up

161 pression (ie, change in score of 5 points on PHQ-9; mean difference, -5.6 points; 95% CI, -6.8 to -4.

162 criptions, and were asymptomatic on PHQ-2 or PHQ-9.

163 via Patient Health Questionnaire (PHQ)-2 or PHQ-9.

164 rd ratios (HRs) per 1-SD higher log CES-D or PHQ-2 adjusted for age, sex, smoking, and diabetes were

165 , wellbeing, shortness of breath, and pain), PHQ-9 scores (12.5 (6, 17.75) vs. 7 (2, 12), p < 0.001),

166 es) and higher order products observed (PHA, PHQ, and LMW oxo- and dicarboxylic acids).

167 h phenanthrene (PHE) or phenanthrenequinone (PHQ) using the aquatic amphipod Hyalella azteca.

168 r phenanthrene (PHE) or phenanthrenequinone (PHQ).

169 AD beginning with a 4-item scale (GAD-2 plus PHQ-2).

170 and categorized using a validated cut point (PHQ-9 >=10).

171 btain point and interval estimates of pooled PHQ-9 sensitivity and specificity at cut-off values 5-15

172 uctured interview reference standard, pooled PHQ-9 sensitivity and specificity (95% confidence interv

173 eek problem area-discordant arm, posttherapy PHQ-9 scores in the 6-week problem area-concordant arm w

174 In clinical practice, PHQ-2 screening seems thus sufficiently reliable and mor

175 ation (156 655 [54.1%] were female) provided PHQ-8 responses.

176 th Initiative Personal Habits Questionnaire (PHQ).

177 tionnaire- the Patient Health Questionnaire (PHQ 15) (plus enhanced iterations including an additiona

178 The Patient Health Questionnaire (PHQ) depression and anxiety modules were administered at

179 g outcomes and Patient Health Questionnaire (PHQ) for depression).

180 sion using the Patient Health Questionnaire (PHQ) has been extensively examined.

181 the validated Patient-Health Questionnaire (PHQ), scoring 10 or greater on the PHQ-9 or scoring 3 or

182 d positive via Patient Health Questionnaire (PHQ)-2 or PHQ-9.

183 assessed using Patient Health Questionnaire (PHQ)-8 in a general European population from 2018 to 202

184 essed with the Patient Health Questionnaire (PHQ)-9 (continuous score, 0-27) at baseline and over tim

185 0.90) and the Patient Health Questionnaire (PHQ)-9 (sensitivity: 0.86; 95% CI 0.70 to 0.94; specific

186 ssed using the Patient Health Questionnaire (PHQ).

187 of the 2-item patient health questionnaire (PHQ-2) versus that of the 9-item version (PHQ-9) to pred

188 version of the Patient Health Questionnaire (PHQ-4).

189 ssessed by the Patient Health Questionnaire (PHQ-9) and anxiety symptoms by the Generalized Anxiety D

190 The Patient Health Questionnaire (PHQ-9) and Generalised Anxiety Disorder (GAD-7) scales w

191 t included the Patient Health Questionnaire (PHQ-9) and the 15-item Mutuality Scale (MS), which asses

192 ssed using the Patient Health Questionnaire (PHQ-9) and the Generalized Anxiety Disorder (GAD-7) scal

193 A 9-item Patient Health Questionnaire (PHQ-9) score of 9 or lower was a prespecified secondary

194 erence in mean Patient Health Questionnaire (PHQ-9) scores at 3 months with secondary analyses over 1

195 da with 9-item Patient Health Questionnaire (PHQ-9) scores of 10 or greater, indicating symptoms cons

196 ts) and 9-item Patient Health Questionnaire (PHQ-9) scores of 10 or greater.

197 s defined by a Patient Health Questionnaire (PHQ-9) total score >=10.

198 n scale of the Patient Health Questionnaire (PHQ-9) was significantly higher at baseline (median, 6.0

199 r above on the Patient Health Questionnaire (PHQ-9) were administered to the standardized computer-as

200 ing the 9-item Patient Health Questionnaire (PHQ-9), a series of psychological traits, and the 5-HTTL

201 on the 9-item Patient Health Questionnaire (PHQ-9), and received a diagnosis of depression during in

202 e (CNS-LS) and Patient Health Questionnaire (PHQ-9), respectively) were obtained from consecutive pat

203 easured by the Patient Health Questionnaire (PHQ-9).

204 sured with the Patient Health Questionnaire (PHQ-9).

205 on the 9-item Patient Health Questionnaire (PHQ-9; score range, 0-27).

206 ng the 8-item Personal Health Questionnaire [PHQ-8]; range, 0-24, higher scores worse) and family-rep

207 ed as a 9-item Patient Health Questionnaire [PHQ-9] score of >=10).

208 the nine-item patient health questionnaire [PHQ-9]).

209 ured using the Patient Health Questionnaire [PHQ]-9), and mental health literacy.

210 ), depression (Patient Health Questionnaire [PHQ]-9), and somatic physical symptoms portions of the P

211 ession (9-item Patient Health Questionnaire; PHQ-9) and device acceptance (Florida Patient Acceptance

212 rtions of the Patient Health Questionnaires (PHQ-15), and the PTSD Checklist for the Diagnostic and S

213 ophoric mono- and polyhydroxylated quinones (PHQ), a different channel produces oxo- and dicarboxylic

214 eeks were depressive symptoms and remission (PHQ-9 and Beck Depression Inventory-II), generalised anx

215 =50% decrease on the CDRS-R), and remission (PHQ-9 score <5).

216 ealth Questionnaire 9-item depression scale (PHQ-9), patient-reported satisfaction with their blood-p

217 tient Health Questionnaire depression scale [PHQ-8]; score range, 0 points [least symptoms] to 24 poi

218 sease reported higher symptoms count scores (PHQ 15: 5.6 (95% CI 5.4 to 5.8) vs 4.2 (4.1 to 4.4) p<0.

219 .0%) were administered depression screening (PHQ-9), and 472 (2.0%) completed anxiety (GAD-7) screeni

220 Among these participants, the mean (SD) PHQ-9 score was 6.5 (6.6), and 25 411 (26.4%) met the cr

221 At baseline, mean (SD) PHQ-9 scores were 14.54 (3.45) in the BA group and 14.31

222 tioner-supported MBCT-SH (n = 204; mean [SD] PHQ-9 score, 7.2 [4.8]) led to significantly greater red

223 itioner-supported CBT-SH (n = 206; mean [SD] PHQ-9 score, 8.6 [5.5]), with a between-group difference

224 For the "standard" PHQ-9 cutoff of 10, accuracy results had been published

225 ignificant increases in depression symptoms (PHQ-9 score, 0.6 points [95% CI, -0.1 to 1.4 points]).

226 5.3; 95% CI, 2.1-8.6), depression symptoms (PHQ-9: aMD, 3.0; 95% CI, 1.5-4.4), and PTSD symptoms (PC

227 e 199 participants with depressive symptoms (PHQ score > or = 10) and 6.7% among the 818 participants

228 icipants, 201 (20%) had depressive symptoms (PHQ score > or =10).

229 for moderate or greater depressive symptoms (PHQ-9 score >=10).

230 t Health Questionnaire-9 Modified for Teens (PHQ-9-M) and the Adolescent Health Questionnaire (AHQ; a

231 -0.86]) was not significantly different than PHQ-9 scores of 10 or greater alone (0.86 [0.80-0.90]);

232 c risk score pleiotropy analyses showed that PHQ-9 symptoms are more associated with traits that refl

233 The PHQ-2 score ranges from 0 to 6, and the PHQ-9 score rang

234 The PHQ-9 depression score increased from 2.4 prior to inter

235 The PHQ-9 showed no difference between the groups (adjusted

236 Eligible studies administered the PHQ-9 and classified current major depression status usi

237 , 2.91; 95% CI, 1.20-4.63; P < .001) and the PHQ-9 (difference, 2.12; 95% CI, 0.68-3.56; P = .004).

238 The PHQ-2 score ranges from 0 to 6, and the PHQ-9 score ranges from 0 to 27.

239 , or both; and (3) how they would answer the PHQ in the future, based on these same 3 options.

240 me measures were depression (measured by the PHQ-2 depression scale) and anxiety (measured by the two

241 ession at 12-week follow-up, measured by the PHQ-8 (secondary outcome).

242 program were eligible, if they completed the PHQ-9 during baseline assessment.

243 After completing the PHQ-8, participants' interpretation of instructions was

244 While there is promising data for the PHQ-2 in other populations, it performed less well than

245 = 0.14 (90% CI, -0.05 to 0.33), and for the PHQ-9 it was d = -0.02 (90% CI, -0.20 to 0.17).

246 tic accuracy statistics were derived for the PHQ-9, GAD-7, and PC-PTSD-5.

247 At a threshold of 3 or greater, the PHQ-3 sensitivity was 0.98 (95% CI, 0.97-0.98) and speci

248 At 3 months, the PHQ-9 adjusted mean difference (AMD) was 0.19 (95% CI -1

249 As use of the PHQ becomes more widespread in practice, additional rese

250 physicians reported that routine use of the PHQ would be useful, new management actions were initiat

251 taining to the measurement properties of the PHQ-15 and SSS-8.

252 te pooled sensitivity and specificity of the PHQ-2 alone among studies using semistructured, fully st

253 (PHQ-2) consists of the first 2 items of the PHQ-9 (which assess the frequency of depressed mood and

254 scored 0 before self-harm or suicide on the PHQ item 9 in the 30- and 90-day cohorts.

255 and psychological assessments, based on the PHQ-15 (Patient Health Questionnaire).

256 on the PHQ-9 or scoring 3 or greater on the PHQ-2.

257 ificantly lowered depression symptoms on the PHQ-9 at 6 weeks and 6 months compared with HealthWatch

258 rty percent of patients scored >or=10 on the PHQ-9 during at least one clinic visit, which correspond

259 ionnaire (PHQ), scoring 10 or greater on the PHQ-9 or scoring 3 or greater on the PHQ-2.

260 depressive symptoms (indicating >=15 on the PHQ-9) and 56 non-depressed controls (indicating <=4) ra

261 nts had results indicating depression on the PHQ-9, 43.3% (52 of 120) showed signs of anxiety on the

262 derate or greater depressive symptoms on the PHQ-9, and 2964 respondents (19.2%) endorsed at least 1

263 creening, 597 women screened negative on the PHQ-9, and one woman did not consent to participate.

264 creening, 562 women screened negative on the PHQ-9, and one woman did not consent to participate.

265 ow the clinical cutoff for depression on the PHQ-9, depressive symptoms were significantly associated

266 pression at 12 months (a score of <=6 on the PHQ-9, with assessors masked to group allocation) in the

267 n the self-harm/suicide risk question on the PHQ-9.

268 n Inventory-II (BDI-II) and remission on the PHQ-9.

269 ce-to-face CBT on the Ham-D (P = .22) or the PHQ-9 (P = .89).

270 liminary data suggests the CESD, HDRS or the PHQ-9 as the most promising options.

271 The two-item PHQ2, the nine-item PHQ9, the PHQ DSM-IV algorithm, and the two-step PHQ2 then PHQ9.

272 Participants completed 2 questionnaires, the PHQ-9 (9-item Patient Health Questionnaire) and the CarC

273 time required of the physician to review the PHQ was far less than to administer the original PRIME-M

274 Four main versions of scoring the PHQ exist.

275 Our study suggests that the PHQ has diagnostic validity comparable to the original c

276 Corresponding symptoms reported through the PHQ-9 and CIDI-SF have low to moderate genetic correlati

277 proteins with an insertion C-terminal to the PHQ motif (GALV I(10)) bind Pit1 but fail to infect cell

278 questions: (1) how they would respond to the PHQ sleep item in a hypothetical scenario where they ove

279 ome was depression symptoms according to the PHQ-9 at 12 months.

280 iety, and loneliness were measured using the PHQ-9, GAD-7, and UCLA Loneliness scale, respectively.

281 ely and in combination with the PHQ-9 vs the PHQ-9 alone for studies that used semistructured intervi

282 10 prespecified secondary outcomes were the PHQ-9 score at 12-month follow-up and the proportion mee

283 When the PHQ-9 was highly sensitive, authors more often reported

284 In samples where the PHQ-9 was poorly sensitive at the standard cutoff, autho

285 hese women consented to be screened with the PHQ-9 (40 women did not consent), of whom 333 (5.2%) scr

286 ssive symptom severity was measured with the PHQ-9 (total score range: 0-27, with a score >=10 indica

287 views separately and in combination with the PHQ-9 vs the PHQ-9 alone for studies that used semistruc

288 over the previous 2 weeks was assessed using PHQ-9 question 9.

289 attacks), and a diagnostic evaluation using PHQ-9 and the Primary Care Evaluation of Mental Disorder

290 with patients receiving treatment as usual (PHQ-9 beta, -0.177 [95% CI, -0.295 to -0.060]; P = .003)

291 atient Health Questionnaire, 9-item version (PHQ-9) scores.

292 e (PHQ-2) versus that of the 9-item version (PHQ-9) to predict death or rehospitalization.

293 0.19 to 0.46 vs. TAS-20, r = 0.07- 0.25 vs. PHQ-9, and r = 0.29- 0.57 vs. GAD-7.

294 The mean 6-week PHQ-9 score was 7.98 (SD 5.63) in the sertraline group a

295 At the primary-outcome point of 52 weeks, PHQ-15 scores were 14.1 (SD 3.7) in the group receiving

296 itivity but higher specificity compared with PHQ-9 cutoff scores of 10 or greater alone.

297 on-years of follow-up among individuals with PHQ-2 scores of 4 or higher vs 0 were 20.9 vs 14.2 for C

298 A similar proportion of participants with PHQ-9 scores less than 9 at baseline who were treated wi

299 Patients with PHQ diagnoses had more functional impairment, disability

300 nd health care use than did patients without PHQ diagnoses (for all group main effects, P<.001).